Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in HBV-related Acute on Chronic Liver Failure
NCT02689245Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of allogeneic fecal microbiota in acute-on-chronic liver failure (ACLF), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Transplant-free survival at 3 months. Started Feb 2016; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT02689245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689245.